Next Phase Newsletter

A East Coast region-based large pharmaceutical specializes in the development of treatments for ultra-orphan diseases (diseases with under 20,000 patients in the USA or EU), and is seeking to in-license novel therapeutics and platforms in this space.

The firm is focused on serving patients and families affected by rare diseases. The firm focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen private equity firm launched by a French family office is headquartered in Paris with additional offices in USA and China. The firm was created with an aim to invest in high growth opportunities in healthcare and multiple other sectors outside of retail. The firm typically makes minority investments of US$2-10 million in Series A and B rounds (either as lead or co-investor in a round). The firm is currently seeking new opportunities in France, United States, and China.

Within healthcare, the firm is interested in digital health applications that improves quality or efficiency of care, such as telemedicine, patient-doctor interface workforce coordination, and analytics software. In particular, the firm’s USA offices are focused on agtech businesses, such as agriculture tech and food. The firm prefers enterprise solutions, but can also consider consumer products. The firm is not interested in insurance, cosmetics, nutraceutical or well-being products. For hardware devices to be considered, it must have a strong software/data component as its core technology. The firm is agnostic to disease areas and is currently most interested in elderly care. The firm prefers to work with growth-stage companies that are revenue-generating.

The firm is looking for companies formed by a team of founders with expertise in the medical, technology, and sales and marketing sectors. One-person companies are less likely to be considered. The firm seeks teams that are able to work across cultures and grow into international markets. The firm is a long-term investor that works closely with its portfolio companies and strives to create a sharing culture together.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital arm of a global pharmaceutical invests in early stage healthcare companies of strategic interest to the parent pharmaceutical (typically seed or series A). The firm has a global mandate and is currently seeking new equity investment opportunities.

As a strategic investor, the firm makes direct equity investments in innovative start-ups aligned with the pharmaceutical’s areas of strategic focus. Among these areas are rare diseases, vaccines, digital health solutions, etc. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data.

The firm has a flexible funding structure and is able to lead and co-lead rounds as well as co-invest with top tier life science investors. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

In addition to equity financing, the firm provides strategic and technical input to portfolio companies through the established expertise of their teams. The success of the firm is driven by the ability to invest in areas where the fund can provide a unique voice and insight, active portfolio company engagement and the facilitation of future strategic collaborations with the parent pharmaceutical.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a large pharmaceutical makes equity investments in life science companies, typically in venture rounds. The firm invests at a wide range of product development phases, from preclinical development (up to 18 months away from the first in-human clinical trials) to products that have received regulatory approval, but typically does not invest in products that are on the market. The fund is open to considering investments globally. The firm makes highly varied investments, with a range from $250,000-$19 million.

The firm invests in areas that are strategically important to the parent company in the medical device and diagnostic sectors. The firm’s medical device interests include cardiovascular devices (traditional vascular, endovascular, arterial, venous, fistula formation, BTK, CLI, neurovascular, structural heart, transcatheter, mitral, pulmonary, EP ablation and afibulation, and implantable cardio devices such as pacers and sensors), diabetes devices (including glucose monitors, new sensing technologies, and other insulin management devices such as pumps), neuromodulation devices (primarily spinal cord stimulators and DBS). Within neuromodulation, the firm is interested in all indication areas that can be impacted by the technology. In diagnostics, the firm is focused on molecular diagnostics, core lab diagnostics, point of care diagnostics, and blood bank testing. In point of care diagnostics, the firm is generally only interested in opportunities that offer a broad panel of tests or which are very specific to a certain setting. The firm is also highly interested in diagnostics for traumatic brain injury and concussion. The firm is also interested in imaging technologies and digital technologies that relate to their core areas.

The firm will invest at any stage of development prior to commercialization; the firm may also consider investing in products that are commercialized overseas but not in the USA.

The firm invests only in privately-held companies, but has no other fixed requirements for companies & management teams. As an investor that provides resources and value in addition to capital, the firm may attach some form of rights to investments, but do not use investment structures that will become a hindrance to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global pharmaceutical company headquartered in Tokyo, Japan is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, the pharma’s R&D team is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney conditions, and rare diseases. The company is currently looking for partnering and in-licensing opportunities across the globe.

The company is currently looking for innovative therapeutics targeting the following priority areas: oncology, pain management, cardiovascular disease, CNS, and rare diseases. Other interest areas include novel therapeutic targets and approaches for the gut microbiome that can modulate disease outcome, cell therapeutics for serious diseases including Stroke/TIA, PAD/CLI and hepatic cirrhosis, and novel therapies for hematological diseases, especially for anemic disorders with erythropoietin resistance. The company is open to biologics or small molecules, with an increased interest in new platform technologies. The following areas are currently out of focus: diabetes, hypertension, dyslipidemia, psychiatric diseases, and immunodeficiency.

The company partners with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with over 15 years of experience is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where the firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large investment firm in Menlo Park, CA, with additional offices throughout the USA and Asia invests broadly in the healthcare and technology sectors, in both venture and growth-stage financing rounds. Due to the firm’s large fund size, the firm generally only invests in rounds that raise $10 million or more. The firm makes investments globally.

Within healthcare, the firm focuses on biopharma, and also invests in medical devices, healthcare IT and healthcare service providers. The firm is generally not seeking opportunities in diagnostics. In biopharma, the firm prefers to invest in companies that have obtained data from human clinical trials; however, the firm also invests in breakthrough therapeutic technologies at the preclinical stage. In medical devices, the firm only invests in growth-stage companies with an approved product and initial revenues; the firm prefers to invest in breakthrough device technologies and avoids commodity markets. The firm has a broad portfolio and is open to any indication area, but has a particular focus in oncology and orphan diseases, and typically does not invest in infectious diseases.

Within the service provision and IT sectors, the firm is focused on opportunities that provide cost savings to the healthcare system; in this sector, the firm’s expertise is primarily in companies that target healthcare providers as customers, but the firm is also open to considering other areas of the services/IT space. The firm has no fixed requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.